Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
IGM Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.
IGM Biosciences Analyst Ratings
Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
IGM Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
IGM Biosciences Analyst Ratings
IGM Biosciences: A Balanced Hold Rating Amid Financial Stability and Drug Development Risks
IGM Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), IGM Biosciences (IGMS) and Optinose (OPTN)
Analysts' Top Healthcare Picks: Inventiva (IVA), IGM Biosciences (IGMS)
RBC Capital Sticks to Their Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences Analyst Ratings
IGM Biosciences Shares Upgraded to Outperform on $1B+ Long-term Opportunity